Abstract
Effective fibromyalgia (FM) treatment requires identification of well-tolerated medications that improve pain and other associated FM symptoms. In 2 randomized, placebo-controlled trials, milnacipran improved multiple FM symptoms and was safe and well-tolerated. To validate these findings, a post hoc analysis of pooled data from these studies was conducted. Both trials were similar in patient selection, study design, and efficacy assessments. Patients received placebo (n = 624), milnacipran 100 mg/day (n = 623), or milnacipran 200 mg/day (n = 837). Two composite responder definitions were used to classify each patient's individual response to therapy. FM responders (overall responders) concurrently satisfied response criteria for clinically meaningful improvements of pain (≥30% improvement from baseline in VAS 24-hour recall pain scores), Patient Global Impression of Change (PGIC, rating of “very much improved” or “much improved”), and physical functioning (≥6-point improvement from baseline in SF-36 PCS scores). FM pain composite responders concurrently satisfied response criteria for clinically meaningful improvements in pain and PGIC. Pooled results at 15 weeks were analyzed by linear mixed-effect models. The percentage of patients who were overall responders was significantly greater in each milnacipran treatment group (23.6%, 200 mg/day; 21.1%, 100 mg/day) compared to placebo (9.6%) (each dose vs placebo, P < .001). Likewise, a significantly greater proportion of milnacipran-treated patients were considered FM pain composite responders (42.8%, 200 mg/day; 36.8%, 100 mg/day) compared to placebo (20.6%) (each dose vs placebo, P < .001). Analysis of individual outcomes indicated significant improvements from baseline with each milnacipran dose compared to placebo in pain (P < .05), global status (P < .001), physical functioning (P < .01), and fatigue (Multidimensional Fatigue Inventory, MFI) (P < .05) at 15 weeks; cognition (Multiple Ability Self-report Questionnaire, MASQ) significantly improved with milnacipran 200 mg/day (P < .01). These results further support the conclusion that milnacipran is effective for the treatment of FM and its associated symptoms. (Supported by Forest Laboratories, Inc. and Cypress Bioscience, Inc.)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.